Media coverage about Veeva Systems (NYSE:VEEV) has been trending somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Veeva Systems earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the technology company an impact score of 45.0486326390205 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern’s rankings:
- Veeva : Cloud Innovation Helps CPG and Chemical Industries Improve Quality Processes (4-traders.com)
- Veeva Cloud Innovation Helps CPG and Chemical Industries Improve Quality Processes (finance.yahoo.com)
- Have a look at up/down Move: Veeva Systems Inc. (VEEV) (mostvolatilestocks.com)
- Spence Asset Management Buys Schwab US Dividend Equity, Cullen/Frost Bankers Inc, Microsoft Corp, Sells Veeva … (gurufocus.com)
- Apple billionaires nowhere to be found, despite it being world’s richest company (afr.com)
Shares of NYSE:VEEV traded down $0.19 during trading on Monday, hitting $71.87. 778,837 shares of the stock were exchanged, compared to its average volume of 1,190,234. The firm has a market capitalization of $10,185.18, a PE ratio of 78.12, a PEG ratio of 4.33 and a beta of 1.39. Veeva Systems has a 1-year low of $50.09 and a 1-year high of $78.28.
A number of research firms have issued reports on VEEV. Vetr raised Veeva Systems from a “buy” rating to a “strong-buy” rating and set a $61.05 target price on the stock in a report on Thursday, February 8th. DA Davidson initiated coverage on Veeva Systems in a report on Friday, February 2nd. They set a “buy” rating and a $75.00 price objective on the stock. Zacks Investment Research lowered Veeva Systems from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. JPMorgan Chase lowered Veeva Systems from an “overweight” rating to a “neutral” rating in a report on Friday, March 9th. Finally, Canaccord Genuity lifted their price objective on Veeva Systems from $70.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, February 28th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $72.23.
In related news, EVP Alan Mateo sold 701 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $58.85, for a total transaction of $41,253.85. Following the completion of the transaction, the executive vice president now owns 9,512 shares in the company, valued at approximately $559,781.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Timothy C. Barabe sold 1,993 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $78.16, for a total value of $155,772.88. The disclosure for this sale can be found here. Insiders have sold a total of 184,831 shares of company stock valued at $13,440,162 in the last 90 days. 17.50% of the stock is owned by corporate insiders.
Veeva Systems Company Profile
Veeva Systems Inc provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, and internationally. The company offers Veeva Commercial Cloud, a suite of multichannel customer relationship management applications, which allow pharmaceutical and biotechnology companies to target and support sales and marketing to physicians, other healthcare professionals, and healthcare organizations through various touch points, including in-person, email, and online; and Veeva Vault, a cloud-based enterprise content management platform and suite of applications for managing commercial functions, including medical, sales, and marketing, as well as research and development functions, such as clinical, regulatory, and quality.
Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.